Caisse DE Depot ET Placement DU Quebec raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 377.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,095 shares of the life sciences company’s stock after buying an additional 7,190 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Illumina were worth $2,540,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of the company. Federated Investors Inc. PA boosted its position in shares of Illumina by 3,088.6% during the first quarter. Federated Investors Inc. PA now owns 492,287 shares of the life sciences company’s stock valued at $116,387,000 after purchasing an additional 476,848 shares in the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Illumina during the first quarter valued at approximately $61,394,000. Summit Trail Advisors LLC boosted its position in shares of Illumina by 21,172.1% during the first quarter. Summit Trail Advisors LLC now owns 194,852 shares of the life sciences company’s stock valued at $195,000 after purchasing an additional 193,936 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Illumina by 4.5% during the second quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after purchasing an additional 185,745 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Illumina by 4,988.1% during the first quarter. Millennium Management LLC now owns 171,674 shares of the life sciences company’s stock valued at $40,587,000 after purchasing an additional 168,300 shares in the last quarter. Hedge funds and other institutional investors own 89.84% of the company’s stock.
Several equities research analysts recently weighed in on the company. BidaskClub lowered Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Piper Jaffray Companies lifted their price objective on Illumina to $380.00 and gave the company an “overweight” rating in a research note on Tuesday. Cowen lifted their price objective on Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a research note on Thursday, September 6th. Argus set a $372.00 price objective on Illumina and gave the company a “buy” rating in a research note on Friday, August 10th. Finally, Morgan Stanley upgraded Illumina from an “underweight” rating to an “equal weight” rating and lifted their price objective for the company from $210.00 to $320.00 in a research note on Tuesday, August 7th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Illumina has a consensus rating of “Buy” and an average price target of $322.56.
Illumina stock traded down $15.19 during mid-day trading on Friday, reaching $329.52. 2,095,647 shares of the stock traded hands, compared to its average volume of 875,165. The stock has a market cap of $53.96 billion, a PE ratio of 82.38, a price-to-earnings-growth ratio of 3.04 and a beta of 0.97. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. Illumina, Inc. has a 12-month low of $198.21 and a 12-month high of $372.61.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The company had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. During the same quarter in the prior year, the business earned $0.82 earnings per share. Illumina’s revenue for the quarter was up 25.4% compared to the same quarter last year. As a group, sell-side analysts predict that Illumina, Inc. will post 5.46 EPS for the current fiscal year.
In other Illumina news, SVP Mostafa Ronaghi sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $288.89, for a total transaction of $2,166,675.00. Following the completion of the sale, the senior vice president now owns 78,496 shares of the company’s stock, valued at $22,676,709.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 500 shares of the company’s stock in a transaction dated Monday, July 23rd. The stock was sold at an average price of $311.15, for a total value of $155,575.00. Following the completion of the transaction, the director now directly owns 6,139 shares of the company’s stock, valued at approximately $1,910,149.85. The disclosure for this sale can be found here. Insiders have sold 49,983 shares of company stock valued at $16,679,124 in the last three months. 0.54% of the stock is currently owned by corporate insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: Does the discount rate affect the economy?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.